Ribo Files EU Trial Application for SR122

The dual-target siRNA therapy is being developed for dyslipidemia, including severe hypertriglyceridemia and mixed dyslipidemia.

Updated on Nov. 11, 2026 in Biotech

Ribo Files EU Trial Application for SR122

Suzhou Ribo Life Science Co. Ltd. submitted a phase I Clinical Trial Application in the EU for SR122, a dual GalNAc-conjugated siRNA therapeutic. The company also said it is progressing phase II clinical studies of its core lipid asset RBD5044 in Europe and China.

Why it matters

Dyslipidemia is a key driver of cardiovascular disease, the leading cause of death worldwide, and patients with mixed dyslipidemia still face substantial residual risk despite current lipid-lowering therapies. SR122 simultaneously targets ApoC3 and PCSK9, a dual approach that has not yet been evaluated in humans.

The filing is a phase 1 clinical trial application, the earliest human-testing stage, for a randomized, placebo-controlled study of subcutaneous SR122 in healthy participants. No human efficacy or safety data for SR122 has been reported, and the trial's start date and readouts were not disclosed.

The players

Suzhou Ribo Life Science Co. Ltd.

Ribo is a Suzhou, China-based biotechnology company developing siRNA therapeutics for cardiovascular and metabolic diseases, with its core lipid asset being RBD5044.

The details

Ribo submitted the Clinical Trial Application to EU regulators on November 11, 2026. The study will provide the first clinical evaluation of the dual-targeting approach in humans and is intended to generate key data to support further development of SR122.

Timeline

  1. November 11, 2026: Ribo announced the EU Clinical Trial Application submission for SR122.

Big Picture

SR122 extends the ApoC3-targeting siRNA approach represented by Ribo's own RBD5044 by adding PCSK9 silencing to the same molecule. Whether combining two lipid targets in one therapy outperforms single-target agents will be tested only once human data emerge.

For patients with severe hypertriglyceridemia, who face increased risk of acute pancreatitis, a therapy that lowers ApoC3 and PCSK9 could eventually offer a new option if clinical trials succeed. The phase 1 study is still at the earliest stage, so no treatment access or pricing changes are expected in the near term.

The takeaway

Dual-target siRNA therapies aim to address residual cardiovascular risk that single-target drugs leave behind. Readers should watch for the first human safety and lipid-lowering data before drawing conclusions about SR122.

Further reading

For more on the science behind these drugs, see the Biotech section.

Source note: This article includes information reported by Pharmabiz.